title: Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.
authors.affiliation: Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA. wang2x2@ucmail.uc.edu
authors.forename: Sean Xiang
authors.initials: SX
authors.lastname: Wang
authors.forename: Abigail
authors.initials: A
authors.lastname: Byrnes
authors.forename: Sadhna
authors.initials: S
authors.lastname: Verma
authors.forename: John R
authors.initials: JR
authors.lastname: Pancoast
authors.forename: Olivier
authors.initials: O
authors.lastname: Rixe
mesh_terms: D000368:Aged; D001557:Benzenesulfonates / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D054796:Drug Dosage Calculations; D016174:Hepacivirus / Q000472:pathogenicity*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008103:Liver Cirrhosis; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D012074:Remission Induction; D000077157:Sorafenib
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib